✦ LIBER ✦

Oligoendrocyte destruction in multiple sclerosis and experimental models of inflammatory demyelination

✍ Scribed by G. Suchanek; V. Barac-Latas; K. Ozawa; H. Lassmann

Book ID: 119109182
Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 154 KB
Volume: 54
Category: Article
ISSN: 0165-5728
DOI: 10.1016/0165-5728(94)90548-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Axon Reactions Precede Demyelination in

Axon Reactions Precede Demyelination in Experimental Models of Multiple Sclerosis

✍ É. Zapryanova; O.S. Sotnikov; S.S. Sergeeva; D. Deleva; A. Filchev; B. Sultanov 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 410 KB

Inflammatory demyelination and neurodege

Inflammatory demyelination and neurodegeneration in early multiple sclerosis

✍ Arnaud Charil; Massimo Filippi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 202 KB

The nature of inflammatory components du

The nature of inflammatory components during demyelination in multiple sclerosis

✍ M.L. Cuzner; G.M. Hayes; J. Newcombe; M.N. Woodroofe 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 980 KB

β2-Adrenoceptor involvement in inflammat

β2-Adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis

✍ Jacques De Keyser; Esther Zeinstra; Jop Mostert; Nadine Wilczak 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 613 KB

Cannabinoids and experimental models of

Cannabinoids and experimental models of multiple sclerosis

✍ Ilona Kubajewska; Cris S. Constantinescu 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 277 KB

[Current Topics in Microbiology and Immu

[Current Topics in Microbiology and Immunology] Advances in multiple Sclerosis and Experimental Demyelinating Diseases Volume 318 || Remyelination in Experimental Models of Toxin-Induced Demyelination

✍ Rodriguez, Moses 📂 Article 📅 2008 🏛 Springer Berlin Heidelberg 🌐 German ⚖ 582 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people